Background Studies suggest a harmful pharmacogenomic interaction exists between short
leukocyte telomere length (LTL) and immunosuppressants in idiopathic pulmonary fibrosis …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity
and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung …

Purpose Real-world studies have reported reduced mortality in patients with idiopathic
pulmonary fibrosis (IPF) treated with antifibrotic therapy; however, the initiation or …

Aims Patients who experience hospitalizations due to heart failure (HF) face a significant risk
of readmission and mortality. Our objective was to evaluate whether the risk of …

Rationale: Idiopathic pulmonary fibrosis (IPF) causes progressive lung scarring and high
mortality. Reliable and accurate prognostic biomarkers are urgently needed. Objectives: To …

Patients affected by idiopathic pulmonary fibrosis (IPF) have a high mortality rate in the first 2–
5 years from diagnosis. It is therefore necessary to identify a prognostic indicator that can …

Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease without a clear
recognizable cause. IPF has been at the forefront of new diagnostic algorithms and …

Extract The antifibrotic medications pirfenidone and nintedanib became the first US Food
and Drug Administration (FDA)-approved medical therapy for the treatment of idiopathic …

Background Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial
lung disease. Clinical models to accurately evaluate the prognosis of IPF are currently …

The incidence of idiopathic pulmonary fibrosis (IPF) has been steadily increasing each year,
posing significant challenges in its treatment. In this study, we conducted the design and …